Clinical Trial Update: TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid [Phase 2]

View source ↗

Summary

Phase 2 trial updating TET2 mutation targeting with azacitidine plus ascorbic acid in myelodysplastic syndromes and acute myeloid leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes
• Myeloproliferative Neoplasm

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Ascorbic acid (Vitamin C)

Snippet

Sponsor: Case Comprehensive Cancer Center | Conditions: Myelodysplastic Syndromes, Myeloproliferative Neoplasm | Phase 2 | Status: COMPLETED